FDA Liver Injury Conference Another Chance To Inform Guidance Changes
This article was originally published in The Pink Sheet Daily
Executive Summary
March event will look at best ways to detect and assess drug liver injury causation as agency mulls reopening the 2009 final guidance.
You may also be interested in...
Jurassic Products: FDA Resurrects Withdrawn Drugs To Study Liver Injury
Agency soliciting contractor to produce 37 drugs withdrawn because of liver injury; goal is developing better tools for evaluating compounds in the pipeline.
FDA Could Shift Assessment Of Drug-Induced Liver Injury In Clinical Trials
Agency officials, industry and academia contemplate a new approach to gauging drug-induced liver injury by using individual patients’ baseline liver enzyme measurements, a move that some say could eliminate problems with the use of the upper limit of normal and allow for the assessment of DILI in cases where there is underlying liver injury.
FDA Prepares To Update Drug-Induced Liver Injury Guidance
A March stakeholder conference is set to consider questions unresolved by the agency's two-year-old guidelines.